The ruling only covers interim relief, so Novo's lawsuit over the comparative ads continues. The company reports nine-month results on November 4.
Recap by typeshit. Full story at ad-hoc-news.de.
AP sources say FDA scientists opposed the HHS draft telling the agency not to act against pharmacies compounding six wellness peptides. Comments are open for two weeks.
Law firm Frier Levitt reads the rule as single-ingredient only, so the popular blend stays out. Public Citizen and ex-FDA official Janet Woodcock voice safety concerns.
Six peptides can now be compounded under strict conditions, but HHS itself says that proves nothing on safety, and research-use-only sellers stay outside the policy.
Compounders get a pass on BPC-157, TB-500 and four others if they meet sourcing and reporting rules. The Alliance for Pharmacy Compounding cheers it, while Public Citizen calls it reckless.
Highlights include a real-world comparison of Wegovy 2.4 mg against resmetirom in MASH and ESSENCE data in people with a BMI under 27, presented Nov. 5 to 9 in Denver.
An investing platform's company history runs from Lilly's 1876 founding through Humulin and Prozac to its obesity drug boom. Background, not news.
Loading…